Gregory Lucier - Catalent Independent Director
Director
Mr. Gregory T. Lucier is a Independent Director of the Company. Mr. Lucier is the Chairman and Chief Executive Officer of Nuvasive, Inc., a medical device company focused on developing minimally disruptive surgical products and procedures for the spine. Prior to joining Nuvasive, Inc. in March 2015, Mr. Lucier was Chairman and Chief Executive Officer of Life Technologies Corporation, a global biotechnology company, from May 2003 until it was acquired by Thermo Fisher Scientific, Inc. in February 2014. Prior to that, Mr. Lucier was a corporate officer at General Electric Company, where he served in a variety of leadership roles. Mr. Lucier is a director of Nuvasive, Inc. and served as a director of Life Technologies Corporation from May 2003 to February 2014 and of Carefusion Corporation from August 2009 until its sale to Becton, Dickinson and Company in March 2015 since 2015.
| Age | 56 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 732 537 6200 |
| Web | https://www.catalent.com |
Catalent Management Efficiency
Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities.Catalent currently holds 4.92 B in liabilities with Debt to Equity (D/E) ratio of 0.9, which is about average as compared to similar companies. Catalent has a current ratio of 2.8, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Catalent's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Richard Wallman | Charles River Laboratories | 69 | |
| John Danhakl | IQVIA Holdings | 64 | |
| George Llado | Charles River Laboratories | 55 | |
| Tania DeVilliers | Bio Rad Laboratories | 51 | |
| Thomas Hofmann | West Pharmaceutical Services | 68 | |
| George Babich | Teleflex Incorporated | 69 | |
| Stuart Randle | Teleflex Incorporated | 61 | |
| Jeffrey Edwards | Bio Rad Laboratories | 60 | |
| Arnold Pinkston | Bio Rad Laboratories | 62 | |
| Richard Packer | Teleflex Incorporated | 62 | |
| JeanPaul Mangeolle | Charles River Laboratories | 57 | |
| Robert Bertolini | Charles River Laboratories | 59 | |
| Gregory Hinckley | Bio Rad Laboratories | 74 | |
| George Massaro | Charles River Laboratories | 73 | |
| Martin Mackay | Charles River Laboratories | 65 | |
| Robert Friel | West Pharmaceutical Services | 65 | |
| James Fasano | IQVIA Holdings | 50 | |
| Colleen Goggins | IQVIA Holdings | 66 | |
| Deborah Kochevar | Charles River Laboratories | 64 | |
| Alice Schwartz | Bio Rad Laboratories | 93 | |
| George Milne | Charles River Laboratories | 77 | |
Management Performance
| Return On Equity | -0.11 | |||
| Return On Asset | -0.0018 |
Catalent Leadership Team
Elected by the shareholders, the Catalent's board of directors comprises two types of representatives: Catalent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalent. The board's role is to monitor Catalent's management team and ensure that shareholders' interests are well served. Catalent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalent's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Castellano, VP of Fin. and Investor Relations and Treasurer | ||
| Paul Surdez, Vice Relations | ||
| Joseph JD, General VP | ||
| Tom PEng, President Delivery | ||
| Trish Hunt, President Health | ||
| Peter Zippelius, Independent Director | ||
| David McErlane, Group Segment | ||
| Steven Fasman, Senior Vice President General Counsel and Corporate Secretary | ||
| Michael Hatzfeld, VP Officer | ||
| Kay Schmidt, Senior Vice President - Technical Operations | ||
| Karen Santiago, VP Office | ||
| Jonathan Arnold, President - Oral & Specialty Delivery | ||
| Ricky Hopson, Division President | ||
| John MBA, Executive Board | ||
| John Chiminski, Chairman of the Board, Chief Executive Officer | ||
| Donald Morel, Independent Director | ||
| John Greisch, Independent Director | ||
| Gregory Lucier, Independent Director | ||
| Rolf Classon, Independent Director | ||
| Michael Barber, Independent Director | ||
| Steven Esq, Corp VP | ||
| Karen Flynn, President - Biologics and Chief Commercial Officer | ||
| Michael Grippo, Senior Vice President - Strategy and Corporate Development | ||
| Matti Masanovich, Senior CFO | ||
| Julien Meissonnier, VP Officer | ||
| Christa Kreuzburg, Independent Director | ||
| Lisa Evoli, Senior Officer | ||
| Madhavan Balachandran, Independent Director | ||
| J Carroll, Independent Director | ||
| Scott Gunther, Senior Vice President - Quality & Regulatory Affairs | ||
| Wetteny Joseph, Chief Financial Officer, Senior Vice President | ||
| Alessandro Maselli, Senior Vice President - Global Operations | ||
| Dejan Lamesic, Head Development | ||
| Ricci Whitlow, President - Clinical Supply Services | ||
| Charles Lickfold, Senior Vice President, Chief Information Officer | ||
| Aristippos Gennadios, President - Softgel & Oral Technologies | ||
| Ricardo Pravda, Chief Human Resource Officer, Senior Vice President | ||
| Jack Stahl, Lead Independent Director | ||
| Z Mahdavi, Vice President of Open Innovation, Biologics, Cell and Gene Therapy | ||
| Rosemary Crane, Independent Director |
Catalent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.11 | |||
| Return On Asset | -0.0018 | |||
| Profit Margin | (0.09) % | |||
| Operating Margin | (0.07) % | |||
| Current Valuation | 16.13 B | |||
| Shares Outstanding | 181.51 M | |||
| Shares Owned By Insiders | 0.50 % | |||
| Shares Owned By Institutions | 87.80 % | |||
| Number Of Shares Shorted | 14.74 M | |||
| Price To Earning | 17.80 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Catalent Stock
If you are still planning to invest in Catalent check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catalent's history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |